This study reports the systematic development of a population-based health screening package for all Thai people under the universal health coverage (UHC). To determine major disease areas and health problems for which health screening could mitigate health burden, a consultation process was conducted in a systematic, participatory, and evidence-based manner that involved 41 stakeholders in a half-day workshop. Twelve diseases/health problems were identified during the discussion. Subsequently, health technology assessments, including systematic review and meta-analysis of health benefits as well as economic evaluations and budget impact analyses of corresponding population-based screening interventions, were completed. The results led to advice against elements of current clinical practice, such as annual chest X-rays and particular blood tests (e.g. kidney function test), and indicated that the introduction of certain new population-based health screening programs, such as for chronic hepatitis B, would provide substantial health and economic benefits to the Thais. The final results were presented to a wide group of stakeholders, including decision-makers at the Ministry of Public Health and the public health insurance schemes, to verify and validate the findings and policy recommendations. The package has been endorsed by the Thai UHC Benefit Package Committee for implementation in fiscal year 2016.
INTRODUCTION
Health screening is defined as a sieving process to identify seemingly healthy people who may be at increased risk of or already affected by a disease or condition, in order to provide proper management and care (Raffle and Gray 2007) . There are two means of providing health screening to a given target population: (1) population-based screening program, defined as a screening systematically offered by invitation to a defined, identifiable population, with close monitoring and evaluation to ensure its quality and coverage, and (2) opportunistic screening, defined as a screening test offered to someone by a health professional (National Health Committee 2003) . Unlike a population-based screening programme, opportunistic screening may not be checked or monitored.
Health screening, however, is not without its limitations, including medical (e.g. false positives or negatives), psychological (e.g. stress from test results), societal (e.g. stigmatisation), and economic (e.g. cost)
prevalence, mortality rate, service utilisation (number and cost of inpatient admissions), disabilityadjusted life years (DALYs) lost, and availability of health screening. All information was reviewed from literature. 1.2 A half-day stakeholder consultation workshop was convened to prioritise health problems, and the participants were allowed to nominate additional health problems if deemed important. A total of 41 stakeholders were divided into three groups: group I-16 technical officers representing all departments within the Ministry of Public Health and academics with experience in conducting health priority setting or health screening research; group II-10 medical practitioners representing royal colleges and medical associations; and group III-15 representatives from non-governmental organisations and lay people identified through a list of these stakeholder groups available at the National Health Commission Office. The list of 35 health problems and related information was circulated to stakeholders 2 weeks before the meeting. The Delphi technique (Vos et al. 2006) was modified and applied in three rounds of prioritisation. In the first round, individual stakeholders were asked to prioritise 10 health problems on the list without ranking in order, based on their opinions. The prioritisation results were summarised by each group of stakeholders. All participants were encouraged to discuss whether they agreed with the first-round results and also to provide their justifications. As such, in the second and the third round, individual stakeholders were asked to rank order five health problems on the original list including additional nominations. Each round of rankings were not intended to shorten the original list but rather to allow stakeholders to deliberate on and share reasons for supporting their prioritisation. After each round of prioritisation, the processes of result summarisation, presentation, and discussion, similar to those of the first round, were conducted. 1.3 Based on Health Intervention and Technology Assessment Program's capacity to carry out assessments in parallel for screening interventions, the top 10 health problems ranked by each of the three groups in the third round were selected as the final list of priority health problems. Detailed analysis of similarities and differences of preference among the three stakeholder groups and associated factors are presented in a separate paper . 2 Assessments of population-based health screening interventions For each priority health problem, the generic process of HTA-that is, identifying and fine-tuning research questions, reviewing literature, selecting the appropriate HTA approach (e.g. literature reviews, economic evaluation, and budget impact analysis), conducting HTA studies, and presenting preliminary results to expert panels to verify and validate research findings and policy recommendations-was applied.
2.1 We carried out a literature review to identify population-based screening interventions for each health problem. Furthermore, document reviews on international experiences of introducing population-based health screening for each priority health problem in Australia, Singapore, the UK, the USA, and the Thai clinical guidelines were performed. 2.2 We convened expert consultation meetings to determine policy-relevant questions for assessments of population-based screening interventions. The experts included medical practitioners and representatives from respective industries and the three public health insurance schemes. The policy questions refer to indicators such as safety, effectiveness, feasibility, cost-effectiveness, and budget impact. 2.3 We conducted HTA studies according to the identified research questions obtained from the previous step. To ensure comparability of results across sub-studies, all HTA studies followed the Thai national HTA guidelines . The preliminary results were presented to the same group of experts in order to verify and validate research findings and policy recommendations. Stakeholder engagement to review the recommended population-based health screening interventions. The overall findings and recommendations of a population-based health screening package were subsequently presented at a half-day meeting to a broad range of stakeholders for verification and validation. The meeting included 90 participants comprised of 35 health professionals/health care providers, 21 patient group representatives, 14 policymakers, 8 representatives from public (payers) and private insurers, 6 academics, and 6 representatives from industrial associations. The recommendations on the screening interventions summarised from this step were then considered by policymaking bodies for the universal health coverage scheme benefits.
RESULTS

Priority health problems that require population-based screening
A total of 12 out of 35 health problems were selected as priorities for further assessment to identify appropriate population-based health screening. Table I provides background information and ranking results of each health problem. The 12 health problems accounted for 66% of the total DALYs, 38% of total number of inpatient admissions, and 57% of the total cost of inpatient services in Thailand. Table II shows information on 16 policy-relevant questions identified for the 12 priority health problems from expert consultation meetings (refer to process 2.2), HTA approaches, and main findings. Ten questions could be assessed by reviewing previous studies on the screening intervention's safety, effectiveness, and costeffectiveness. The other six questions required local evidence on economic evaluation. Of these, five questions needed budget impact analysis. Details of six economic evaluation studies conducted for assessing health screening interventions following the policy-relevant questions are presented in Table III .
Assessment of population-based health screening interventions
From the main findings of HTA studies, four screening interventions were not recommended because the review identified no availability of population-based screening interventions (for cholangiocarcinoma and asthma), evidence of possible harm (chest X-ray for population-based screening of asymptomatic tuberculosis), and no evidence on effectiveness (urinary analysis and renal function tests for screening of nephritis, nephrosis, and renal calculi). Mammography for breast cancer was not recommended because of the fact that it does not represent good value for money given that the best option, which is once in a lifetime mammographic screening for women aged 40-49 and 50-59 years, yields an incremental cost-effectiveness ratio (ICER) of 1 847 000 and 1 369 000 baht/quality-adjusted life year (QALY) gained, respectively.
In total, seven population-based health screenings were recommended based on economic evaluations of which the ICERs ranged between cost saving to 136 000 baht/QALY, which is lower than the present ceiling threshold of 160 000 baht/QALY recommended by the sub-committee for the development of the universal health coverage benefit package and service delivery in Thailand . These interventions included the following:
• Screening for cardiovascular diseases using global risk score (blood pressure, cholesterol level, waist circumference, blood sugar level, and smoking status) for those aged 35 and over every 5 years • Diabetes screening using fasting plasma glucose for those aged 30 years and over every 5 years • Screening for alcohol, tobacco, and drug use using verbal screening by the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for populations aged 15-60 years every year • Screening for chronic hepatitis B using hepatitis B surface antigen and anti-HBs once in a lifetime for those ages between 31 and 40 years • Screening for chronic hepatitis C once in a lifetime for HIV-infected patients • Cervical cancer screening using pap smear or visual inspection by acetic acid for women 30-60 years old every 5 years
• Provider-initiated counselling and testing (screening) for HIV There were four interventions recommended for population-based screening in Thailand even though there was no local cost-effectiveness result because they are effective interventions with very low or no cost for introduction. These include (1) pulse palpation for populations aged 65 years or older for every visit to a health facility to detect atrial fibrillation; (2) complete blood count for infants aged 9-12 months who visit health All costs were converted to price year 2012. Further information regarding the standard cost menu can be found from Riewpaiboon (2014) .
USING HTA FOR DEVELOPING THE HEALTH SCREENING PACKAGE facilities to receive mumps, measles, and rubella vaccination to detect iron deficiency anaemia; (3) a series of recommendations focusing on body mass index and verbal screening on food consumption in order to detect malnutrition and over-nutrition; and (4) visual acuity screening for populations aged 60 years and above who hold a lifetime driving license to prevent traffic accidents caused by the elderly. A total of 11 population-based health interventions were recommended for the Thai population based on age, sex, and frequency of screening (Figure 1 ). The estimation of the budget impact for implementing this package indicated that it would cost 380-400 baht per capita (15 years and above) per year on average or 19 000-20 000 million baht per year.
Stakeholder engagement
The recommendations for the health screening benefit package were presented to a wide range of stakeholders on 4 March 2013 (refer to process 3), which were well received with only a few minor comments, for example, the need for pilot studies for a program, such as hepatitis B and C screening, which had never been Utility: derived from an economic evaluation of traztuzumab for treating breast cancer in Thailand implemented in Thailand. The meeting participants also discussed governance for implementing the recommended package, monitoring and evaluation of its impact, and revising the package in the future.
DISCUSSION
This study describes the use of HTA to inform the comprehensive package of population-based health screening in a middle-income country. It is evident that economic evaluation can play an important role in decisionmaking, although it is not necessary to include it in every assessment of health screening interventions, for example, when there is no intervention available or a lack of effectiveness evidence and the potential harm outweighs the benefits. Based on our experience, economic evaluation for health screening poses methodological challenges because most studies that assess efficacy or effectiveness of screening interventions usually only report the sensitivity and specificity of the test. There are only a few studies that address the final health outcome or impact of screening, such as population morbidity and mortality. Therefore, model-based health economic evaluation is applied as a main approach in order to estimate short-and long-term costs and consequences of screening. It was found that a majority of the health screening interventions considered in the study are cost-effective (Figure 2) , especially in comparison with no screening leading to delayed treatment. The delayed treatment is an appropriate comparator in the Thai health care setting because Thailand provides universal access to treatment of all diseases (Mohara et al. 2012; . Another reason for good value for money is that the health problems addressed have a high disease burden and associated screening interventions are likely to have high yield, that is, all of the interventions lead to early detection and reduce future burden of caring for and treating common diseases, resulting in good value for money. In the case of breast cancer screening, the economic evaluation results showed that Thailand has a much lower disease incidence and prevalence compared with Western countries (Ferlay et al. 2013) , which contributed to excluding population-based screening for breast cancer and instead indicated that the health care system should focus on primary prevention, such as smoking cessation, obesity control, and treatment of breast cancer. In addition, the cost-effectiveness analyses used a societal perspective and adopted a lifetime time horizon, so short-and long-term benefits of health screening were appropriately counted in the analyses. In the literature review, a number of economic evaluations of health screening were identified, but only a few adopted cost-utility analyses. The majority of studies used cost-effectiveness approaches (reported in terms of cost per case detected) (Petrou et al. 2000; Pattanaphesaj and Teerawattananon 2010) , resulting in a tendency for high cost per one case detected because the screening applies to a majority of the population whereas the cases detected occur only in some. On the contrary, this study considers potential savings from late treatments as a result of early detection, showing that many health screening interventions were cost-saving.
This study also illustrates how HTA can be incorporated into policy mechanisms for the development of the benefit package. Figure 3 illustrates that stakeholders can play a significant part in making the benefit package development systematic and feasible. For instance, stakeholders can prioritise topics for assessment using explicit criteria and a deliberative process, help fine-tune research questions and the scope of study, and verify and validate preliminary results as well as fine-tuning policy recommendations. Once final results have been obtained and policy recommendations on the package as a whole have been formed, a stakeholder consultation meeting can help to verify and validate the benefit package. Note that stakeholders involved in each group may or may not be the same, depending on the context of each meeting. We believe that this process is robust and can be powerful to systematically develop and legitimise policy-relevant HTA information.
Regarding the method of HTA, it is unlikely that only one approach is enough to address policy concerns. Although economic evaluation can provide significant information on whether an intervention is worthwhile, decision-makers and stakeholders also request for other information, such as disease burden, Figure 2 . Incremental cost-effectiveness plane illustration of selected screening interventions public acceptance (through prioritisation and consultation), budget impact, and affordability. Because this study focused on population-based screening under the universal health coverage in Thailand, meaning that options are considered to actively provide screening to all eligible populations using public finances, equitable access to screening in terms of financial barriers is no longer an issue. However, it may be the case that even though the service is in need and health care providers provide it freely-supply-the eligible population may not access the service because of the lack of knowledge and awareness or geographical restrictions. In this regard, health care providers need to address the issue of raising awareness and make the service more geographically accessible, for example, in communities. This issue is related to package implementation. At this stage of the design, issues that are considered are synergic options of the health interventions in the package, offering several screening interventions in the same setting and at the same frequency (Figure 1 , which collates our recommendations and is used for communication with providers and the public). This is different from other HTA studies on treatment because poor and vulnerable populations are likely to have limited access.
Given that the appropriateness of health screening depends on many factors such as disease burden, health system infrastructure, level and mechanism for health financing, etc., the results of this study may not be generalisable across settings; however, the approach, that is, process and methods, may be applicable. Screening interventions that are cost-effective in Thailand may not represent good value for money in other settings. However, the HTA process is more generalisable.
In addition, the synergies across health interventions were considered in this study. For example, in the assessment for alcohol dependence/harmful use, both Alcohol Use Disorders Identification Test and ASSIST are cost-effective interventions; however, the researchers opted for ASSIST because the tool is also useful for screening of smoking. Therefore, the selection of ASSIST has a synergic effect in the implementation of cardiovascular disease screening, of which smoking is one of the major risk factors. Another example is the Figure 3 . Health technology assessment process used in developing health screening package in Thailand USING HTA FOR DEVELOPING THE HEALTH SCREENING PACKAGE current screening of diabetes mellitus (DM) every 5 years (versus annually) in order to screen DM and global risk assessment simultaneously. This is a practical advantage and promotes incentives for people to screen for global risk of CVD as well, because there is less awareness for this issue in Thailand.
Deliberative process was on the prioritisation of disease and health problems for assessment of screening interventions. The availability of screening in the Thai health system was discussed, but other issues, for example, human resources, equipment, or facility shortages, were not discussed because the meeting focused on prioritisation and the group of stakeholders at the meeting, such as lay people and civil society, were not the appropriate group to discuss such issues. However, the shortage issues were discussed after prioritisation in a subsequent meeting comprised of health experts and industry for each disease and health problem before assessment. In these meetings, the shortages of human resources, equipment, and facilities were discussed in order to identify key screening interventions that were worthwhile for assessment under the Thai setting. As a result, interventions that were not feasible in real policy were automatically excluded from the process, for example, the exclusion of liquid-based pap smear for screening of cervical cancer because of the lack of feasibility.
Not all health screening is necessarily favourable in terms of health and economic consequences. Many health screening programs with evidence of unfavourable impact were excluded in the process. For example, screening of prostate cancer was excluded because of a consensus during the prioritisation process that there is clear evidence against population-based screening of prostate cancer. Other examples are chest X-rays among general population (no proven effectiveness) and screening for hepatitis C among general population (strong expert opinion against this approach because of low disease prevalence).
This study had some limitations. First, because of the limited capacity to carry out assessments in parallel for screening interventions, the screening package was proposed with constraints of 12 priority health problems; there are other screening interventions outside those 12 health problems that proved to be cost-effective in the Thai context and should be considered for coverage decision, such as prenatal screening for Down's syndrome (Pattanaphesaj and Teerawattananon 2010) and refractive error screening in pre-primary and primary school children . Second, no referral to treatment system, once the positive results were detected from the screening, was considered as a result of this study.
The results of this study were presented to the UCS authorities, and the proposed screening package was accepted in November 2014. The national program will start in October 2015. In addition, the policy recommendations by the UCS authorities include educating the general population about the rational use of health screening through various public communication channels.
